Effect of physical activity on the course of inflammatory bowel disease
DOI:
https://doi.org/10.12775/QS.2024.15.52425Keywords
inflammatory bowel disease, Crohn disease, ulcerative colitisAbstract
The inflammatory bowel disease (IBD) group includes ulcerative colitis (UC), Crohn's disease (CD) and microscopic enteritis. In UC, the lesions involve only the large intestine and do not cross the mucosa, while CD can involve any part of the gastrointestinal tract, from the mouth to the anus. Inflammatory bowel disease usually occurs between the ages of 20-30, with another peak incidence in the seventh decade of life. The etiology of inflammatory bowel disease is not fully understood. Diagnosis is made on the basis of clinical evaluation, endoscopic examination with histopathological evaluation and imaging studies. Treatment involves the introduction of an appropriate diet, and pharmacological, biological and surgical treatments are used. The prognosis is inauspicious, with inflammatory lesions often recurring, even after years of remission of the disease. The purpose of this paper is to describe in detail the two most common diseases in the inflammatory bowel disease group, highlighting the differences and similarities between them at the level of lesion localization, symptoms, diagnosis and treatment. Patients with inflammatory bowel disease, due to the accompanying symptoms that make daily activities difficult, are less active than healthy people. There is ample evidence of the beneficial effects of physical activity on quality and length of life. It is recommended to conduct moderate intensity of both endurance and resistance exercises.
References
Yulan Y, Zhi P, Weichang C, et al. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med., 2015; 8 (12): 22529-22542.
Namysłowska K, Adler G. Epidemiologia, patogeneza i diagnostyka choroby Leśniowskiego-Crohna. Diagnostyka Laboratoryjna, 2023; 59 (1): 8-16.
Hebzda A, Szczeblowska D, Serwin D, et al. Choroba Leśniowskiego-Crohna – diagnostyka i leczenie, Pediatr Med Rodz, 2011; 7 (2): 98-103.
Glinkowski S, Marcinkowska D. Ulcerative colitis: assessment of disease activity based on contemporary scales. Borgis - Nowa Medycyna, 2018; 3: 123-137.
Zawadzka P. Inflammatory bowel diseases – in the past and now. Nowiny Lekarskie, 2006; 75 (5), 480–485.
Ralston S, Penman I, Strachan M, et al. Davidson Choroby wewnętrzne, 2020; 2 (23): 304-315.
Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol, 2005 Dec 14; 11 (46): 7227-7236.
Troncoso LL, Biancardi AL, de Moraes HV Jr, Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. World J Gastroenterol, 2017 Aug 28; 23 (32): 5836-5848.
Petagna L, Antonelli A, Ganini C, et al. Pathophysiology of Crohn’s disease inflammation and recurrence, BMC, 2020; 23: 1-10.
Mrowicki J, Mrowicka M, Majsterek I. Czynniki środowiskowe zwiększające ryzyko aktywacji i rozwoju chorób zapalnych jelit, Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, Łódź, Postępy Biochemii, 2020; 66 (2): 167-175 .
Singh B, Schwartz D. Assessing severity of disease in patients with ulcerative colitis. Gastroenterol Clin N Am, 2020; 49 (4): 671-688.
Radwan P, Radwan K, Skrzydło-Radomańska B. The treatment of severe acute attacks of ulcerative colitis. Gastroenterologia Polska, 2013; 20 (1): 5-10.
Nelke M. Genetyczna i kliniczna charakterystyka chorych z wrzodziejącym zapaleniem jelita grubego. Katedra i Klinika Chirurgii Ogólnej i Kolorektalnej Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, 2013.
Gołąbek K., Regulska- Ilow B. Jakie produkty wyeliminować, a jakie wprowadzić do diety osób z chorobami zapalnymi jelit? Problemy higieny i epidemiologii, 2018; 99 (2): 114-121.
Jasyk D, Paradowska A. Oral Manifestations of Crohn’s Disease. Copyright by Silesian Piasts University of Medicine in Wrocław and Polish Stomatological Association Dent. Med. Probl., 2008; 45 (2): 199–205.
Feuerstein J, Cheifetz A. Crohn Disease: Epidemiology, Diagnosis, and Management. Mayo Clinic Proceedings, 2017; 92 (7): 1088-1103.
Satsangi J, Silverberg M, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut, 2006; 55 (6): 749-753.
Sheth T, Pitchumoni CS, Das KM. Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease. Gastroenterology Research and Practice, 2015; 2015: 1-11.
Licona Vera E, Betancur Vasquez C, Peinado Acevedo JS, et al. Ocular Manifestations of Inflammatory Bowel Disease. Cureus, 2023 Jun 12; 15 (6): e40299.
Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World Journal of Gastroenterology, 2003, 9 (10): 2300-2307.
Steell L, Gray SR, Russell RK, et al. Pathogenesis of Musculoskeletal Deficits in Children and Adults with Inflammatory Bowel Disease. Nutrients, 2021 Aug 23; 13 (8): 2899.
Ali A, Schmidt M, Piskin D, et al. Epidemiology of Musculoskeletal Manifestations in Pediatric Inflammatory Bowel Disease: A Systematic Review. ACR Open Rheumatology, 2022 Jun; 4 (6): 547-554.
Antonelli E, Bassotti G, Tramontana M, et al. Dermatological Manifestations in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2021 Jan 19; 10 (2): 364.
Yarur AJ, Czul F, Levy C. Hepatobiliary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2014 Sep; 20 (9): 1655-1667.
Ryżko J, Kawalec W, Grenda R, et al. Pediatria. Wydawnictwo Lekarskie PZWL, Warszawa, 2016; 1 (11): 489-493.
Wojtuń S, Gil J, Szwed Ł, et al. Basic symptoms and differentiation of inflammatory bowel diseases, Pediatr Med Rodz, Warszawa, 2014; 10 (1): 61–66.
Feuerstein J, Cheifetz A. Ulcerative Colitis: Epidemiology, Diagnosis, and Management. Mayo Clinic Proceedings, 2014; 89 (11): 1553-1563.
Dobrowolska-Zachwieja A, Jakubowska-Burek L. Profits from biological treatment in inflammatory bowel disease patients. Przegląd Gastroenterologiczny, 2010; 5 (2): 68–76.
Caio G , Lungaro L, Caputo F, et al. Nutritional Treatment in Crohn’s Disease. Nutrients, 2021; 13 (5): 1628.
Pithadia A, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacological Reports, 2011; 63 (3): 629-642.
Rieder F, Zimmermann E, Remzi F, et al. Crohn’s disease complicated by strictures: a systematic review. Gut, 2013; 62 (7): 1072–1084.
Rozich J, Holmer A, Singh S. Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases. The American Journal of Gastroenterology, 2020; 115:832-840.
Bilski J, Mazur-Biały A I, Wierdak M, et al. The impact of physical activity and nutrition on inflammatory bowel disease: the potential role of cross talk between adipose tissue and skeletal muscle. Journal of physiology and pharmacology, 2013: 64 (2): 143-155.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Natalia Piątkowska, Magdalena Kajzar, Małgorzata Rodak, Kamila Nitka, Magdalena Iwan, Błażej Szymczuk, Joanna Smorońska-Rypel, Dominik Trojanowski, Jakub Milczarek, Ksawery Adamiec
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 143
Number of citations: 0